More selective interactions of nanoparticles with cells would substantially increase their potential for diagnostic and therapeutic applications. Thus, it would not only be highly desirable that nanoparticles can be addressed to any cell with high target specificity and affinity, but that we could unequivocally define whether they rest immobilized on the cell surface as a diagnostic tag, or if they are internalized to serve as a delivery vehicle for drugs. To date no class of targets is known that would allow direction of nanoparticle interactions with cells alternatively into one of these mutually exclusive events. Using MCF-7 breast cancer cells expressing the human Y 1 -receptor, we demonstrate that G protein-coupled receptors provide us with this option. We show that quantum dots carrying a surface-immobilized antagonist remain with nanomolar affinity on the cell surface, and particles carrying an agonist are internalized upon receptor binding. The receptor functions like a logic "and-gate" that grants cell access only to those particles that carry a receptor ligand "and" where the ligand is an agonist. We found that agonist-and antagonistmodified nanoparticles bind to several receptor molecules at a time. This multiligand binding leads to five orders of magnitude increased-receptor affinities, compared with free ligand, in displacement studies. More than 800 G protein-coupled receptors in humans provide us with the paramount advantage that targeting of a plethora of cells is possible, and that switching from cell recognition to cell uptake is simply a matter of nanoparticle surface modification with the appropriate choice of ligand type.
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nanoparticle targeting | drug delivery | quantum dots | nanoparticle receptor interaction | cell membrane binding A goal of biomedical targeting is the selective delivery of nanoparticles to a specific mammalian tissue of interest for diagnostic or therapeutic purposes (1) (2) (3) . Current strategies for guiding nanoparticles to their target have focused mainly on immobilizing either antibodies against cell surface proteins (4-6) or natural ligands for cell surface receptors (7) on particle surfaces. The substantial molecular mass and size added to the nanoparticles decreases the utility of attached antibodies, and receptor ligands have not provided us with the necessary versatility to date. Only a few receptors, such as the transferrin receptor or the epidermal growth factor receptor, have emerged as targeting sites (4, 7) , which are unfortunately expressed in a multitude of tissues and are therefore rather unspecific.
In addition to these severe limitations, a problem of paramount significance is the loss of control over such particles' fate once they bind to their target. To date, no mechanism is known that would allow us to design particles destined for a single target structure such that they can be addressed exclusively to the cell surface or alternatively to the cell interior. The former would allow us to use particles for diagnostic purposes without interfering with intracellular processes; the latter would enable us to elicit a cellular response in cells identified by nanoparticles. Despite the tremendous progress toward a better understanding of factors having an impact on particle uptake by cells, such as size and surface charge (8-10), a fundamentally new strategy to control nanoparticle trafficking has yet to be developed.
In following this strategy, it was necessary to use a whole new family of targets for which ligands are available that are not only highly tissue type specific but that allow "sorting" of particles after binding. The family of G protein-coupled receptors (GPCRs), which exhibit high tissue specificity and represent the largest class of receptors in the human genome (11), appeared to be a promising choice. High-affinity ligands for GPCRs of moderate molecular mass exist, and early reports have indicated that liganddecorated nanoparticles still interact with the receptor (12, 13) . Most importantly, however, two classes of GPCR ligands exist: agonists that lead to receptor internalization upon binding and antagonists that do not (14) .
Having identified such a potential "molecular switch" for controlling the gateway into cells, we hypothesized that the immobilization of an agonist on a nanoparticle surface would cause cellular uptake, although the immobilization of an antagonist to a particle would result in arrest on the cell surface. Furthermore, we believed that such nanoparticles will preserve their high cell affinity and target specifity by attaching to cell surface receptors via a multiligand binding mode.
To investigate the validity of both hypotheses, we selected the human neuropeptide Y (NPY) Y 1 -receptor as a model receptor. This receptor has an incidence of 85% in breast carcinoma and 100% in lymph node metastases (15) . We used quantum dots (QDs) (16) , to which peptidic agonists of a few kilodaltons in molecular mass or a small-molecule antagonist were attached, to examine whether GPCR trafficking upon ligand binding (17) can be exploited as a selective nanoparticle gateway into cells.
Results and Discussion
Different peptidic agonists of the Y 1 -receptor, analogs of porcine NPY (pNPY) exhibiting different receptor affinities and molecular masses (Table 1) , were synthesized (SI Materials and Methods and Fig. S1 ). The introduction of a cysteine residue by side-chain modification of a lysine found in the selected agonists (18) (19) (20) provided a specific reaction site for the stable covalent linkage to the QDs. As shown in Fig. 1A , amino-PEG coated QDs were rendered thiol-reactive upon treatment with sulfosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (sulfo-SMCC), subsequently reacted with the peptides and purified by gel filtration chromatography (details of the conjugation Author contributions: A.G. designed research; W.H., K.P., and R.R. performed research; A.C., C.C., M.K., N.P., and A.B. contributed new reagents/analytic tools; W.H., K.P., A.B., J.T., M.B., and A.G. analyzed data; and W.H., M.B., and A.G. wrote the paper.
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This article is a PNAS Direct Submission. and purification procedure can be found in SI Materials and Methods). Transmission electron microscopy images confirmed that this strategy yielded monodisperse (SI Materials and Methods and Fig. S2 ), peptide-modified ( Fig. S3 ) QDs, a schematic illustration of which is shown in Fig. 1B . Similarly, QDs decorated with a low molecular mass, nonpeptidic antagonist were prepared. For the attachment to the QDs, a thiol was introduced into the antagonist BIBP3226 by acylation with 6-mercaptohexanoic acid to (Table 1) (for details of BIBP and SH-BIBP synthesis, see SI Materials and Methods and Fig. S4 ).
Both agonist-and antagonist-modified QDs were investigated by confocal laser scanning microscopy (CLSM) to observe binding to the human breast cancer cell line MCF-7, which expresses the Y 1 -receptor (cell culture conditions and details of CLSM investigations are provided in SI Materials and Methods). Both QD types exhibited highly specific binding (Figs. 2 and 3). To assure that ligand-free QDs are not internalized by any unspecific uptake mechanism, NPY Y 1 -receptor-positive MCF-7 cells were incubated under the conditions described for ligand-modified nanoparticles. Fig. 4 shows that there is no significant uptake of the particles. Further control experiments showed that binding is specific to the Y 1 -receptor, as no binding was observed either to MCF-7 cells in the presence of free antagonist BIBP3226 or when conducting the experiment with MDA cells lacking the receptor. Both agonist-and antagonist-modified QDs exhibited specific cell binding, but there was a tremendous difference with respect to cellular uptake. Only agonist-modified QDs were internalized. The cells formed vesicular structures containing agonist-modified QDs, which indicate that the nanoparticles had been transported into the cells (Fig. 2) . The internalization of these particles was corroborated by confocal z-stack images. To further elucidate the location of agonist-modified particles after their interaction with cells, images representing optical sections through the cells were taken from MCF-7 cells after incubation with [Lys 4 (N α -Acetyl-Cys), Arg ]-pNPY-QDs. As depicted in Fig. 5 , strong fluorescence because of the QDs can be found throughout the cells, except for the cell nuclei. This finding supports the concept that the particles were effectively delivered into the target cells. The cells show spots in the cytoplasm that are typical of endocytotic vesicles formed upon receptor-mediated endocytosis. In the case of antagonist-modified particles, the fluorescence was strictly limited to the cell membrane, indicating that particles were located on the cell surfaces only (Fig. 6) . Similar results concerning binding and internalization were obtained when repeating the experiment with SK-N-MC cells, another Y 1 -receptor-positive cell line derived from the central nervous system (Fig. S5 ). This result clearly demonstrates (21)]. In summary, our results show that GPCRs can be used to target nanoparticles specifically either to the target cell's surface or to its intracellular compartment by simply attaching an antagonist or an agonist, respectively, to the particle surface. After demonstrating that GPCRs can function as selective gateways, we investigated if tagged nanoparticles still exhibited a sufficiently high affinity toward their receptor. This theory is of concern for future in vivo applications, which demand that particles accumulate reliably at the target site in the presence of competing unspecific binding sites that may exist. Binding curves of QDs modified with the agonist [Lys4( α N-Acetyl-Cys), Arg6, Pro34]-pNPY (Fig. 7A ) and the antagonist SH-BIBP, respectively (Fig. 7B) , were recorded for Y 1 -receptor-positive MCF-7 cells using MDA cells as a negative control (for details of binding and displacement studies see SI Materials and Methods). The resulting saturation of binding sites and the low nonspecific binding indicate that the particles bind specifically to the receptor. Similar results were obtained for the other two agonistic peptides (Fig. S6) . When we calculated the concentrations at which 50% of the binding sites are occupied (the dissociation constant, K d ), the values were ≈21 nM for agonist-modified and approximately 30 nM for antagonist-modified QDs (Table S1 ). These values reflect that the nanoparticles, even though their ligands were chemically altered, still possess a superb affinity for the receptor. To further confirm the specificity of the interaction with cells, we investigated the binding behavior of particles in a competitive binding assay with unbound Y 1 -receptor antagonist BIBP3226. As expected, both agonist-and antagonist-modified QDs can be displaced from the receptors almost completely (Fig. 7 C and D) . However, we found that very high amounts of BIBP3226 were needed to displace the nanoparticles from the receptor. For 1-nM agonist-modified particles, the inhibitory constant (IC 50 , reflecting the concentration at which BIBP3226 displaces 50% of the particles) ranged from 640 to 1,550 μM (Fig. S6 and Table S1 ). This result is approximately five orders of magnitude higher than values usually obtained for the free agonist according to the literature (22) . The results were similarly striking for the antagonist-modified QDs. For the halfmaximum displacement of 1 nM of antagonist-modified (i.e., BIBP3226-modified) QDs, again a five-order of magnitude excess of free BIBP3226 was needed. We hypothesize that such a tremendously high affinity of the agonist-and antagonist-modified particles compared with the free antagonist is attributed to the fact that nanoparticles can bind to several receptors at a time, a phenomenon that is referred to as "multiligand binding" (23) (24) (25) . This finding is strongly supported by other examples in the literature in which monovalent ligands were found to poorly displace multivalent particles or molecules subject to multiligand binding (25, 26) .
The results that we obtained have a number of significant implications for the delivery of nanoparticles to cells. With GPCRs, we have a precious tool in our hands that allows us to target a multitude of cells in an organism with exceptional high specificity. Currently, there are more than 800 receptors known for humans and approximately 1,800 in rats and mice (27) . This means, if we want to direct nanoparticles to a certain tissue, we only have to pick the appropriate GPCR for the respective tissue from a database (28) , choose the appropriate ligand for this GPCR, and tether it to the nanoparticles surface as an "address label," a strategy that resembles a building-block principle. Besides the high target specifity, the paramount advantage of GPCR targeting is that we can control the particles' fate after binding to the cell surface by the activation of a logic-gate cascade: by choosing an agonist for the interaction with the receptor we open the gate into cells, or by selecting an antagonistic ligand we leave it closed. This strategy, which needs to be scrutinized for other GPCRs and further agonist/antagonist combinations, has the potential to outdistance by far other sophisticated approaches with antibodies that also demonstrate a highly specific binding (29) , but are associated with accepting the subsequent fate of the particle as it is. In the future this could lead to concepts where we first design antagonistic nanoparticles to identify cells inside a tissue or an organism, and where in a second step, agonistic particles can be used for therapeutic purposes to deliver nanoparticles via the same target structure into the same cell type.
In addition, our results have implication even beyond the obvious fact that we can reproducibly target particles either to the cytosol or the cell surface. The findings reported here may be unique in representing a step to granting us access to a toolbox currently only employed by viruses that allows them to achieve outstanding target cell specificity. By binding to several different cell surface proteins at the same time, viruses unequivocally identify their target cell and make use of a single additional interaction to trigger cell internalization (30, 31) . If we would like to mimic this strategy using nanoparticles, we would have to design multiligand binding particles that allow for target identification by tagging the cell surface in a first step, followed by triggering cell entry. Our results have obviously shown that GPCRs would be ideal target candidates that have the potential to exactly meet these requirements. GPCR-binding nanoparticles can thus be used as a tool to explore in more depth how targeting and trafficking of particles in vivo can be optimized. Simultaneously, they are allowing us to take advantage of their mechanism for a multitude of biotechnological applications, such as receptor-mediated siRNA delivery into cells for which we recently developed a unique type of carrier (32) . Although more research is necessary to further tailor the targeting and uptake events for specific tissues, the remarkable biological and pharmaceutical implications of such "dual-action" nanoparticles indicates this is an exciting line of future inquiry with broad-ranging applications.
Materials and Methods
Buffers and Reagents. All chemicals were obtained from Sigma in the highest purity available, unless stated differently. Activation buffer consisted of 50 mM sodium tetraborate buffer, pH 7.2. Purification buffer I consisted of activation buffer, supplemented with 150 mM sodium chloride and 10 mM EDTA (EDTA) disodium salt. Conjugation buffer contained two parts of purification buffer I and one part of dimethylformamide, whereas purification buffer II contained DMSO instead of dimethylformamide and 0.01% sodium azide. The ultrafiltration units had a 100-kDa cutoff membrane (Amicon Ultra-4; Millipore). Incubation medium consisted of phenol red-free Leibovitz F-15 Medium (Invitrogen), 1% BSA, and 0.01% Bacitracin (Invitrogen).
Synthesis of pNPY Analogs. Three analogs of the pNPY were synthesized by standard automated solid-phase synthesis. Lysine in position 4 was modified by side-chain attachment of an additional cysteine residue for the bioconjugation with the QDs. The sequences of the peptides are given in Table 1 . The mass was confirmed by MALDI-TOF-MS using α-cyano-4-hydroxycinnamic acid matrix (SI Materials and Methods).
Synthesis of BIBP3226 and SH-BIBP. BIBP3226 and SH-BIBP were synthesized based on a procedure published previously for other N G -substituted derivatives of BIBP3226 (21) (SI Materials and Methods and Fig. S4 ).
Conjugation of Y 1 -Receptor Ligands to QDs. One nanomole of QD 655 ITK amino (PEG) QD (Invitrogen) was transferred into 200 μL of activation buffer by buffer exchange using ultrafiltration (Amicon Ultra-4, 100K MWCO; GE Healthcare). The QDs were subsequently activated by a 500-fold molar excess of sulfo-SMCC dissolved in activation buffer to yield a final volume of 250 μL. After 30 min of gentle shaking at room temperature, the activated QDs were purified by gelfiltration chromatography using purification buffer I as mobile phase (for details see SI Materials and Methods and Fig. S3 ). After buffer exchange to conjugation buffer, removal of the excess conjugation buffer by ultrafiltration, and concentration to a volume of 100 μL, QDs were incubated with a 30-fold excess of the respective NPY-analog or a 100-fold excess of SH-BIBP for 12 h at 4°C. Thereafter, a 100-fold molar excess of 2-mercaptoethanol was added to quench unreacted maleimides. After 30 min, the obtained bioconjugate was purified again by gel-filtration chromatography using purification buffer II. Subsequently, the conjugate was concentrated by ultrafiltration to a final concentration of 3 μM that was used for the biological studies.
Cell Culture. The human breast-cancer cell line MCF-7 and the human neuroblastoma cell line SK-N-MC were maintained in Minimum Essential Medium containing Earl's salts supplemented with 5% FBS (FBS). Forty-eight hours before the experiments, MCF-7 cells were seeded in the same medium supplemented with 1 nM estradiol (Sigma) to increase the receptor density (33) . SK-N-MC cells were cultured in the absence of estradiol. MDA cells were Imaging and CLSM. Two days before the experiments, cells were seeded in 8-well micro-slides (Ibidi). All experiments were conducted in incubation medium at 37°C. Cells were observed using a Zeiss Axiovert 200M inverted epifluorescence microscope coupled with a LSM 510 laser scanning device, using a 40× Plan-Apochromat water-immersion objective (NA 1.2). QDs and QD/ligand-conjugates were excited using the 488-nm line of an Ar-laser. Emission was measured using a 650-nm long pass filter. For the investigation of agonist-and antagonist-modified QD interactions with MCF-7 cells by z-stack images, we used as slice thickness of 1.1 μm for agonist-modified QDs and 1.8 μm for antagonist-modified QDs.
Binding and Displacement Studies. Cells were seeded in 24-well plates at a density of 130,000 (MCF-7) and 80,000 (MDA) cells per well. For the studies, the medium was removed, cells were washed with PBS, and incubated with the QD dilutions for 2 h at 23°C. After incubation, the QDs were removed and the cells were washed with PBS and trypsinized. After centrifugation at 200 × g at 4°C, the cells were washed twice with cold PBS and used for FACS analysis.
For association curves, the respective amount of the testing substance was diluted in incubation medium. For displacement studies, all ligand-modified QDs were used at a concentration of 1 nM. The incubation medium contained the respective amount of BIBP3226 and 7.5% DMSO to increase the solubility of the antagonist.
Cells were analyzed on a FACSCalibur (BD Biosciences). QDs were excited at 633 nm via a diode laser and emission was measured using a 661/16-nm bandpass filter. Data were analyzed by using the WinMDI 2.8 software. The population representing whole cells (on average 20,000 cells) was gated and the fluorescence was plotted in a histogram. All values were corrected for the background signal obtained in the absence of QDs. For binding studies, the intensities of the geometric mean of the histogram were plotted. For displacement studies, the intensity of the geometric mean obtained for 1 nM of the respective QD sample without antagonist was set to 100%, and all other samples were calculated proportional to this value. Each data-point represents the mean of three independent measurements (±SEM). All data to be fitted were processed with SigmaPlot 8.0. Data from binding experiments were evaluated by one-site saturation fits. Data from displacement experiments were analyzed by four-parameter sigmoidal fits. 
